Advice

following a full submission

eluxadoline (Truberzi®) is not recommended for use within NHS Scotland.

Indication under review: in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).

Eluxadoline showed superiority over placebo in producing a composite response, which included abdominal pain response and stool consistency response, in patients with IBS-D.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Download detailed advice335KB (PDF)

Download

Medicine details

Medicine name:
eluxadoline (Truberzi)
SMC ID:
1292/18
Indication:
in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).
Pharmaceutical company
Allergan Ltd
BNF chapter
Gastro-intestinal system
Submission type
Full
Status
Not recommended
Date advice published:
15 January 2018